NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.80
−1.18%Oct 12, 2026, 22:26 UTC
Nurix Therapeutics reported quarterly earnings of $4.73 per share, compared with a loss of $1.03 per share a year earlier.
Source:Oct 12, 2026, 20:05 UTC
Nurix Therapeutics, Inc. dosed the first patient in the Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL.
Source:Oct 7, 2026, 05:00 UTC
Nurix Therapeutics announced that the first patient was enrolled in its Phase 1b/2 NX-5948-203 study of bexobrutideg combined with venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma.
Source:Oct 5, 2026, 11:00 UTC
Nurix Therapeutics and Gilead Sciences agreed to extend the research term for an undisclosed oncology program within their ongoing strategic collaboration by an additional two years.
Source:Aug 20, 2026, 11:00 UTC
Nurix Therapeutics appointed Wes Burwell as its Chief Human Resources Officer on August 20, 2026.
Source:Aug 11, 2026, 05:21 UTC
Nurix Therapeutics' stock reached a new 52-week high of $26.04 on Tuesday after Royal Bank of Canada raised its price target.
Source:Aug 4, 2026, 11:00 UTC
Nurix Therapeutics earned a $10 million milestone payment after collaborator Sanofi initiated a Phase 1 clinical trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases.
Source:Jul 21, 2026, 20:01 UTC
Nurix Therapeutics announced HSR clearance for its global collaboration with Roche to co-develop and co-commercialize bexobrutideg.
Source:Jul 9, 2026, 22:26 UTC
Nurix Therapeutics, Inc. reported its quarterly financial results for Q2 2026, with a loss of $0.81 per share.
Source:Jun 26, 2026, 16:05 UTC
Nurix Therapeutics entered a collaboration with Roche for bexobrutideg, including a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.